The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ORGANIZATION
ORGANIZATION
- Chuikyo Rep Interview 2-1 - As Japan Sees More Pricey Meds, Kenporen Director Wants Rethink of Health Coverage
October 10, 2023
- Eliminate Authorized Generics as They Hamper Competition: JMA
October 10, 2023
- Global CEOs Want Positive Sign from Japan, Sentiments Drive Decisions: EFPIA Chief
October 6, 2023
- Chuikyo Rep Interview 1 - JPA Vice President Warns against Rushed Dabate on Yakkasa, 2% Buffer Zone
October 4, 2023
- Japan Drug Wholesalers’ Workforce Down 3% for 2nd Year: JPWA Survey
October 3, 2023
- Generic Use Rate Reaches Record 81.7% in April-June: JGA
September 29, 2023
- Assess Evaluation Methods for Innovative Medical Products: Science Council
September 28, 2023
- Ex-MHLW CMO Calls for Reasonable Pricing of Alzheimer’s Drugs
September 27, 2023
- Shipments Restricted or Halted for 22.9% of Products in August: FPMAJ
September 25, 2023
- JPMA Embarking on Creation of One-Stop Platform for Rare Disease Trial Info
September 19, 2023
- Hiroyasu Kitagawa Named New Chief of Kyokai Kenpo
September 19, 2023
- JPMA Optimistic on New Minister’s Commitment on Boosting Innovation: Exec
September 15, 2023
- 4 Cell & Gene Therapies Represent 90% of Top 100 Bills in FY2022: Payer
September 8, 2023
- Single-Wholesaler Model Has No Merits for Hospitals: Hyogo Doctors Group
September 7, 2023
- Industry Calls for Clear Criteria for SaMD Reimbursement to Boost Predictability
September 5, 2023
- HIV Groups Pin Hopes on MHLW’s Development Requests for Preventive Therapy
September 4, 2023
- Only 1.2% of NSCLC Patients Receiving Gene Panel Tests: Survey
September 1, 2023
- Shipments Restricted or Suspended for 22.4% of Products in July, No Sign of Improvement: FPMAJ
August 31, 2023
- JPMA on Alert for IRA’s Drug Pricing Provisions, Boosting Cooperation with PhRMA
August 29, 2023
- As 2040 Doctor Shortage Looms, Japan Consumer Healthcare Group Pushes Rx-to-OTC Switches for Hypertension Meds
August 25, 2023
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…